Taro Achieves Global Resolution of DOJ Antitrust Investigations
Under a Deferred Prosecution Agreement reached with the DOJ, the DOJ will file an Information for conduct that took place between 2013 and 2015. If the Company adheres to the terms of the agreement, including the payment of
The Company is discussing a separate Corporate Integrity Agreement with the
“We are happy to have reached this global resolution with the DOJ,” said
About Taro
Taro is a science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro, please visit the Company’s website at www.taro.com.
SAFE HARBOR STATEMENT
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the subject DOJ investigation. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Forward-looking statements are applicable only as of the date on which they are made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005915/en/
VP, CFO
(914) 345-9001
Daphne.Huang@Taro.com
AVP, Business Finance, Treasurer and Investor Relations
(914) 345-9001
William.Coote@Taro.com
Source: